Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for cystic fibrosis by targeting and stabilizing the CFTR protein, particularly its nucleotide-binding domain 1 (NBD1). The company is advancing a pipeline of small molecule drugs designed to address the underlying genetic mutations in CF, aiming to deliver differentiated and clinically meaningful benefits to patients. Sionna is recognized for its innovative approach and leadership in the cystic fibrosis therapeutics market.

Company Facts

• Headquarters: Waltham, United States
• Founded: 2019
• Employees: 41
• Type: Public Corporation
• Website: https://www.sionnatx.com
• Industries: Biotechnology, Pharmaceuticals, Life Sciences, Drug Development